Acusera 24.7 – Interlaboratory Data Management Reporting Software

Home - Quality Control

Acusera 24.7 – Interlaboratory Data Management Reporting Software

Acusera 24•7 is a live, cloud based interlaboratory data management and peer group reporting software, intended to assist in the management of daily QC activities.

Designed to complement our range of Acusera true third party controls.

 

 

Key Benefits of Acusera 24•7

null

Peer Group Statistics

Updated live in real-time, labs can compare statistics to their peers and identify any unique or widespread issues to help reduce time and money spent on troubleshooting.

null

Fully Interactive Charts

Ability to compare performance, assess trends and monitor performance with automatically generated Levey-Jennings, Histograms and Performance Summary Charts.

null

Highly Flexible

Labs can configure their own performance limits, multi-rules, consensus groups and target values for each instrument or lot of QC.

null

Unique Dashboard Interface

Reduce time spent analysing data as instant identification of any QC failures over the past 7 days and alerts of product expiry are highlighted in the unique dashboard design.

null

Comprehensive Reports

Comprehensive, easy-to-read and customisable reports have been designed to speed up the review process and include Statistical Metrics, Uncertainty of Measurement, Exception, Audit Trail & more.

null

24/7 Access

Gain access to this cloud-based software at anytime, anywhere. Removing the need installation, software maintenance and frequent back-ups.

null

Advanced Statistical Analysis

Automatically calculating advanced statistics including %Bias, Total Error and Sigma Metrics helps enhance performance assessment, improve QC strategy, and meet regulatory requirements.

null

Automated Data Import

Upload QC data directly to Acusera 24•7 via LIMS and middleware. This automated function eliminates the need for manual data entry and helps save money whilst increasing efficiency.

null

Technical Support

Expert technical support is available for users. Laboratories can access this service for troubleshooting purposes and therefore eliminates the need for on-site assistance.

What does Acusera 24•7 provide?

247 Diagram-01

Continue Reading

Acusera 24•7 FAQs

Acusera 24•7 Login

Acusera 24•7 Brochure

Acusera 24•7 Packages

Contact Us


Acusera 24.7 Software Update

The latest update of Acusera 24.7 has officially launched, allowing RX Imola, RX Modena and RX Daytona+ users to import compatible QC data files from a configured analyser to Acusera 

 

Acusera 24•7 | Update Features

Our brand new Acusera 24.7 video is here! Take a look now

 

 

Want to know more?

Contact us or download our Acusera 24.7 brochure today.

Continue Reading

Acusera 24.7 FAQs

Resource Hub

Quality Controls


Whole pathogen multiplex controls to support testing for cold, cough and COVID

News       Coronavirus        Qnostics

 

27 October 2020

Whole pathogen multiplex controls to support testing for cold, cough and COVID

Just in time for flu season, global diagnostics company Randox Laboratories has unveiled a range of whole pathogen multiplex controls that cover multiple viral and bacterial pathogens which cause respiratory disease.

Inclusive of SARS-CoV-2, Influenza A & B, and Respiratory Syncytial Virus (RSV), the Qnostics Multiplex Respiratory Pathogen Controls (RTX) facilitate diagnosis of the likes of cold and flu, and importantly, the differentiation of these respiratory diseases from COVID-19.

Using a control line that covers a range of respiratory pathogens in this way will allow laboratories to streamline their testing, consolidate QC, and ultimately save time, money and resource.

Lynsey Adams, Randox Quality Control Manager, explained;     

“When the use of time and resources are critical such as in COVID-19 testing, the use of highly characterised controls enables laboratories to meet their daily QC needs and accreditation requirements.

“Accurate and reliable laboratory testing is an essential aspect of the management of COVID-19 and other respiratory diseases, so we are pleased to be able to offer these new controls which will crucially support the validation, verification and performance monitoring of molecular respiratory assays.”

The new RTX controls, which are whole pathogen for compatibility with the majority of commercial and in-house assays, are used to monitor the full testing process, from extraction to amplification and detection.

The Multiplex Respiratory Controls will support public health testing strategies during the incoming flu season and are suited for the test menus of most syndromic assays.

Lynsey continued;

“The Randox Qnostics Multiplex Respiratory Pathogen Controls are clinically relevant for full-process validation. Liquid frozen for user convenience and ease of use, the development of the controls using whole pathogen material ensures clinical relevance from extraction to amplification and detection.”

Randox Qnostics Multiplex Respiratory Pathogen Controls are manufactured to ISO 13485 standards and are in line with ISO 15189:2012 regulatory requirements.

Key Features and Benefits of the new RTX Controls:

  • Whole pathogen controls – the controls contain the entire genome meaning they are compatible with the majority of commercial and in-house assays.
  • Full process control – whole pathogen controls are the ideal material for full-process validation, monitoring the testing process from extraction to amplification and detection, to ensure ultimate quality assurance in laboratories.
  • Highly characterised – Qnostics controls are quantified by digital PCR to ensure batch to batch reproducibility and are traceable to an internal reference preparation, to ensure metrological traceability of test results obtained by different diagnostic workflows.
  • True Third Party – An independent, unbiased assessment of assay performance is ensured in line with ISO 15189:2012 regulatory requirements.
  • Superior ManufacturingQnostics controls are manufactured under ISO 13485 guidelines to ensure quality and traceability.
  • Liquid for Ease-of-Use – the controls are conveniently supplied in a liquid frozen format meaning there is no additional preparation or handling required.

For more information visit https://www.randox.com/molecular-infectious-disease-controls/respiratory-infection-testing/

For further enquiries please email marketing@randox.com

QNOSTICS

QCMD

CORONAVIRUS


Troponin T Quality Control

Therapeutic Drug Quality Control

Intended for use with the Roche system, this control is manufactured using only the highest quality material and offers an unrivalled 7-day thawed stability at +2ºC to +8ºC.

Features & Benefits

  • Liquid for ease-of-use stability
  • 100% human serum
  • Ultra low levels of Troponin T
  • Stable to expiry date at -18-24ºC storage
  • Thawed stability of 7 days at 2°C – 8°C
DescriptionSize AnalytesCat No 
Troponin T Control6 x 3 ml1CQ10450

Analytes

  • Ultra low Troponin T

Linearity Verifier Sets

Contact Us

Challenge your Instrument Throughout the Reportable Range with Acusera Linearity Verifier Sets

  • null
    Complimentary data reduction software is provided delivering an immediate indication of performance.
  • null
    Samples are provided in a user-friendly format with both liquid and lyophilised options available.
  • null
    An extended open vial stability keeps waste to a minimum and ensures availability of product for troubleshooting.
  • null
    Supplied in a minimum of 5 levels to accurately challenge the AMR and remove the need for manual dilution.
  • null
    Ensure specific instrument requirements are met with the availability of dedicated solution for both Roche Cobas and Beckman systems.
  • null
    Multi-analyte calibration verifiers will reduce costs, storage space and the number of products required to cover your test menu.
Solutions for Roche Cobas Analysers

 

Solutions for Beckman Analysers

 

Calibration verification or linearity assessment is defined as the testing of materials of known concentration in the same manner as patient specimens to ensue the test system is accurately measuring samples throughout the reportable range.

CLIA recommend calibration verification once every six months and/or in the event of; a reagent lot change, major preventative maintenance, replacement of critical parts, when QC materials are outside acceptable limits or reflect an unusual trend and as part of new instrument validation.

Our Acusera range of instrument dedicated verifiers are designed to challenge the entire analytical measuring range whilst helping to meet the CLIA requirements. Our range covers Clinical Chemistry, Bilirubin, Apolipoproteins, Enzymes, CRP, Esoterics, Lipids, TDM‘s and more.

Quality Control

Resource Hub

Contact Us


CE marking granted to Quality Control for newborn infectious disease tests

08 June 2020

CE marking granted to Quality Control for newborn infectious disease tests 

ToRCH Quality Controls to support the accuracy and reliability of infectious disease testing in newborns, have been granted CE marking.

The controls for ToRCH, which is a blood test screening to detect infectious diseases including toxoplasmosis, rubella, cytomegalovirus, and herpes simplex, are available from global diagnostics company Randox Laboratories, and are used to ensure accurate ToRCH test and system performance.

Manufactured from human plasma, each control is designed to react to the test system in the same manner as the patient sample, helping laboratories to meet ISO 15189:2012 for quality and competence.

Lynsey Adams, Randox Quality Control Manager, commented;

“The CE marking of the ToRCH controls from Randox will be a game-changer for clinicians and patients alike, by facilitating early, accurate and comprehensive diagnoses of infectious diseases in newborns, that allow for the best possible patient outcomes.

“Ultimately, these ToRCH controls will guarantee quality assurance in laboratories performing ToRCH screening in newborns.”

Randox ToRCH Controls are also multi-analyte and therefore, testing can be consolidated to just a small number of vials to save laboratories valuable space and time.

In addition to ToRCH, Randox Infectious Disease Quality Controls also include quality control material for Lyme Disease, Epstein-Barr virus, HIV, Hepatitis A virus, Human T-lymphotropic virus, Cytomegalovirus, and Varicella zoster virus (Chickenpox or Shingles).

Lynsey continued;

“Unlike analyser-specific tests, these controls can be used across a wide range of laboratory technologies, and complement our already existing RIQAS Serology EQA programmes to provide laboratories with a complete QC solution from a single supplier.

“With a working stability of 60 days at 2°c to 8°c which keeps waste and costs to a minimum, Randox Infectious Disease Controls are set to revolutionise serology testing and provide reliable, accurate results time and time again.”

Randox Infectious Disease Controls are ideal for microbiology and virology laboratories, blood banks, public health laboratories or clinical laboratories performing serology testing.

Key benefits of the Randox Infectious Disease Controls;

  • User-friendly – all samples are provided in a liquid, ready-to-use format
  • Commutable – manufactured from human plasma, each control reacts to the test system in the same manner as a patient sample
  • Versatility – designed to deliver an independent, unbiased assessment of performance with any immunoassay instrument
  • Stability – working stability of 60 days ensures waste and costs are kept to a minimum
  • Multi-marker – helps reduce the number of individual controls required
  • Clinical relevance – designed to challenge clinically-relevant levels, samples will ensure accurate and reliable instrument performance

For more information visit https://www.randox.com/torch-controls/

QUALITY CONTROL

REAGENTS

RX SERIES


Whole pathogen molecular controls for SARS-CoV-2 (COVID-19) receive CE marking

News       Coronavirus        Qnostics

 

25 May 2020

Whole pathogen molecular controls for SARS-CoV-2 (COVID-19) receive CE marking

CE marking has been granted to whole pathogen quality controls for SARS-CoV-2 (COVID-19), from global diagnostics company Randox Laboratories.

The molecular controls are currently being used alongside the firm’s pioneering COVID-19 tests, performed on its proprietary Biochip, as part of a nationwide UK testing programme.

Randox is using these third-party quality controls, which include a Positive Control, Negative Control, Analytical Q Panel and Molecular Q Panel, to ensure accurate coronavirus test and system performance, and ultimately, guarantee laboratory quality assurance.

Lynsey Adams, Randox Quality Control Manager, explained;     

Accurate and reliable laboratory testing is an essential aspect of COVID-19 disease management and outbreak control.

“Designed specifically for laboratories currently managing COVID-19 testing, Randox SARS-CoV-2 controls, which have been CE marked, help ensure the accuracy and reliability of molecular assays used in the testing of suspected coronavirus samples, and importantly, give clinicians absolute confidence in any COVID-19 diagnoses they may make.”

Available under the brand name Qnostics, the new SARS-CoV-2 controls are manufactured using whole pathogens. They therefore mimic the patient sample, providing the best sample matrix for laboratories.

Lynsey continued;

“The Randox Qnostics SARS-CoV-2 controls are clinically relevant for full-process validation. Liquid frozen for user convenience and ease of use, the development of the controls using whole pathogen material ensures clinical relevance from extraction to amplification and detection.”

The new coronavirus controls from Randox, which contain the entire SARS-CoV-2 genome, including the conserved regions recommended by CDC and WHO, are compatible for use with both commercial and in-house testing methods, and are quantified by digital PCR to ensure batch to batch reproducibility.

Lynsey added;

“We are proud to be able to support the high demand for coronavirus testing by delivering a full COVID-19 testing package – not only our Coronavirus Biochips but now also the corresponding molecular control material that will ensure the delivery of accurate, and reliable results.

 “The World Health Organization (WHO) has been very clear about the importance of testing in the global efforts to contain and delay COVID-19 and we are pleased that our new CE-marked controls comply with guidelines not only from the WHO but also from the Centres for Disease Control and Prevention.”

Randox Qnostics SARS-CoV-2 Controls are heat-inactivated to be non-infectious and are manufactured to ISO 13485 standards.

Key Features and Benefits of Randox SARS-CoV-2 Qnostics Controls:

  • Whole pathogen – the controls contain the entire SARS-CoV-2 genome meaning they are compatible with the majority of commercial and in-house assays, and target the CDC and WHO consensus sequences
  • Monitor the entire testing process – whole pathogen controls are the ideal clinically relevant material for full-process validation, from extraction to amplification and detection, to ensure ultimate quality assurance in laboratories.
  • Non-infectious – the controls are heat-inactivated and gamma-irradiation enabling safe handling of material.
  • Highly characterised – the controls are quantified by digital PCR to ensure batch to batch reproducibility.
  • Clinically relevant – performance data is available to support the clinical relevance and the compatibility with molecular assays currently in use in clinical laboratories.
  • High Quality – the controls are manufactured under ISO 13485 guidelines and are therefore suitable for a broad range of usage.
  • Liquid for Ease-of-Use – conveniently supplied in a liquid frozen format meaning there is no additional preparation or handling required.
  • Complete QC package – Analytical and Molecular Q Panels available for new assay validation as well as routine performance monitoring.

For more information visit www.randox.com/coronavirus-randox

 

QNOSTICS

QCMD

CORONAVIRUS


Qnostics SARS-CoV-2 Controls

Qnostics

Respiratory Target Multiplex (RTX) 1 Control

This multiplex control has been designed in response to the current Coronavirus pandemic. The control can be used to support the validation, verification and performance monitoring of molecular assays used in SARS-CoV-2 testing and other respiratory pathogens.

Meeting the requirements of various testing strategies, this 4-plex control covers multiple viral pathogens that cause respiratory diseases in various patient cohorts, in line with public health testing and the test menu of most syndromic assays.

Having a multiplex control, like the Qnostics RTX1, gives great flexibility to laboratories and allows them to meet laboratory requirements in terms of respiratory pathogens covered whilst keeping QC tests to a minimum.

Features & Benefits

  • null
    Whole Pathogen Control

    Containing the entire SARS-CoV-2 genome, the RTX1 Control is compatible with the majority of commercial and in-house assays. As a whole pathogen control, it targets the whole viral genome.

  • null
    Full Process Control

    Whole pathogen controls are ideal for full-process validation, monitoring the testing process from extraction to amplification and detection ensuring ultimate quality assurance in laboratories.

  • null
    Highly Characterised

    Using highly characterised controls enable labs to meet their daily QC needs and accreditation requirements. Qnostic controls are quantified by digital PCR to ensure batch-to-batch reproducibility.

  • null
    True Third Party

    An independent, unbiased assessment of assay performance is ensured in line with ISO 15189:2012 regulatory requirements.

  • null
    Liquid for Ease-of-Use

    Conveniently supplied in liquid frozen format meaning there is no additional preparation or handling required.

Specification

Target Pathogen – Influenza A (H1N1), Influenza B (Victoria), Respiratory Syncytial Virus (A), Coronavirus (SARS-CoV-2)

Target – Whole Pathogen

Matrix – Transport Medium

Format – Liquid Frozen

Stability – Single use. Once thawed use immediately.

Regulatory Status – RUO

Ordering Information

Catalogue Number Product Description Pack SizePackage Insert
RTX1QCRTX1 Q Control5 x 0.6 mlKit Insert

SARS-CoV-2 (COVID-19) Control

In response to the current Coronavirus outbreak, Qnostics, a world leading manufacturer of QC solutions for molecular infectious disease testing has developed a range of products designed to support the validation, verification and performance monitoring of molecular assays used in the testing of SARS-CoV-2 (COVID-19). Accurate and reliable laboratory testing is an essential aspect of COVID-19 disease management and outbreak control. The use of third-party controls will allow laboratories to effectively monitor the performance of diagnostic methods. For more information on Qnostics click here

Features & Benefits

  • null
    Whole Pathogen Control

    Qnostics controls contain the entire SARS-CoV-2 genome meaning they are compatible with the majority of commercial and in-house assays.

  • null
    Full Process Control

    Whole pathogen controls are ideal for full-process validation, monitoring the testing process from extraction to amplification and detection ensuring ultimate quality assurance in laboratories.

  • null
    Negative Control Available

    Negative controls contain human cells/nucleic acids and therefore can be used as part of assay validation.

  • null
    True Third Party

    An independent, unbiased assessment of assay performance is ensured in line with ISO 15189:2012 regulatory requirements.

  • null
    Complete QC Solution

    Products available for new assay validation as well as routine performance monitoring.

Specification

Target Pathogen – SARS-CoV-2 (COVID-19)

Target – Whole Pathogen

Matrix – Transport Medium

Format – Liquid Frozen

Stability – Single use. Once thawed use immediately.

Regulatory Status – CE, RUO

Q Controls

Whole pathogen controls designed to monitor assay performance on a run to run basis. As true third party controls, assay drift is detected, monitored and managed helping to ensure accurate and reliable results.

Ordering Information

Catalogue Number Product Description Pack Size
SCV2QCSARS-CoV-2 Q Control5 x 0.5 ml
TMNQCNegative Q Control 5 x 0.5 ml

Specification

Target Pathogen – SARS-CoV-2 (COVID-19)

Target – Whole Pathogen

Matrix – Transport Medium

Format – Liquid Frozen

Stability – Single use. Once thawed use immediately.

Regulatory Status – CE, RUO

Analytical Q Panels

Designed to span the analytical measuring range of an assay, allowing assessment of linearity, Limit of Detection (LOD) and Limit of Quantitation (LOQ).

Ordering Information

Catalogue Number Product Description Pack Size
SCV2AQPSARS-CoV-2
Analytical Q Panel
9 x 0.5 ml

Specification

Target Pathogen – SARS-CoV-2 (COVID-19)

Target – Whole Pathogen

Matrix – Transport Medium

Format – Liquid Frozen

Stability – Single use. Once thawed use immediately.

Regulatory Status – CE, RUO

Molecular Q Panels

Four individual levels including a negative are provided spanning the assays’ clinical range. Molecular Q Panels may be used to support laboratory training and in the performance assessment and validation of molecular diagnostic assays.

Ordering Information

Catalogue Number Product Description Pack Size
SCV2MQPSARS-CoV-2
Molecular Q Panel
4 x 0.5 ml

Randox unveils whole pathogen molecular controls for SARS-CoV-2 (COVID-19)

News       Coronavirus        Qnostics

 

16 April 2020

Randox unveils whole pathogen molecular controls for SARS-CoV-2 (COVID-19)

Whole pathogen quality controls to support accurate coronavirus testing have been developed by scientists in the UK.

The molecular controls, available from global diagnostics company Randox Laboratories, are currently being used as part of a nationwide testing programme for frontline NHS workers.

Alongside its pioneering COVID-19 tests, performed on its proprietary Biochip, Randox is using these third-party quality controls to ensure accurate coronavirus test and system performance, and ultimately, guarantee laboratory quality assurance.

Lynsey Adams, Randox Quality Control Manager, explained;     

Accurate and reliable laboratory testing is an essential aspect of COVID-19 disease management and outbreak control.

“Designed specifically for laboratories currently managing COVID-19 testing, Randox SARS-CoV-2 controls help ensure the accuracy and reliability of molecular assays used in the testing of suspected coronavirus samples, and importantly, give clinicians absolute confidence in any COVID-19 diagnoses they may make.”

Available under the brand name Qnostics, the new SARS-CoV-2 controls are manufactured using whole pathogens. They therefore mimic the patient sample, providing the best sample matrix for laboratories.

Lynsey continued;

“The Randox Qnostics SARS-CoV-2 controls are clinically relevant for full-process validation. Liquid frozen for user convenience and ease of use, the development of the controls using whole pathogen material ensures clinical relevance from extraction to amplification and detection.”

The new coronavirus controls from Randox, which contain the entire SARS-CoV-2 genome, including the conserved regions recommended by CDC and WHO, are compatible for use with both commercial and in-house testing methods, and are quantified by digital PCR to ensure batch to batch reproducibility.

Lynsey added;

“We are proud to be able to support the high demand for coronavirus testing by delivering a full COVID-19 testing package – not only our COVID-19 tests on the Randox Biochip, but now also the corresponding molecular control material that will ensure the delivery of accurate, and reliable results.

 “The World Health Organization (WHO) has been very clear about the importance of testing in the global efforts to contain and delay COVID-19 and we are pleased that our new controls comply with guidelines not only from the WHO but also from the Centres for Disease Control and Prevention.”

Randox Qnostics SARS-CoV-2 Controls are heat-inactivated to be non-infectious and are manufactured to ISO 13485 standards.

Key Features and Benefits of Randox SARS-CoV-2 Qnostics Controls:

  • Whole pathogen controls – the controls contain the entire SARS-CoV-2 genome meaning they are compatible with the majority of commercial and in-house assays, and target the CDC and WHO consensus sequences
  • Monitor the entire testing process – whole pathogen controls are the ideal clinically relevant material for full-process validation, from extraction to amplification and detection, to ensure ultimate quality assurance in laboratories.
  • Non-infectious – the controls are heat-inactivated and gamma-irradiation enabling safe handling of material.
  • Highly characterised – the controls are quantified by digital PCR to ensure batch to batch reproducibility.
  • Clinically relevant – performance data is available to support the clinical relevance and the compatibility with molecular assays currently in use in clinical laboratories.
  • High Quality – the controls are manufactured under ISO 13485 guidelines and are therefore suitable for a broad range of usage.
  • Liquid for Ease-of-Use – the controls are conveniently supplied in a liquid frozen format meaning there is no additional preparation or handling required.
  • Negative controls available – delivering a complete testing package.

For more information visit www.randox.com/coronavirus-randox

QNOSTICS

QCMD

CORONAVIRUS


Request a meeting
×
Make an Enquiry - RX series
×
Make an Enquiry - Reagents
×
Kit Insert Request - Reagents
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Kit Insert Request - Reagents
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Make an Enquiry - Reagents
×
Make an Enquiry - Quality Control
×
Make an Enquiry - RIQAS
×
Make an Enquiry - RIQAS
×
Make an Enquiry - Quality Control
×
Make an Enquiry
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Make an Enquiry - Biochip
  • This field is for validation purposes and should be left unchanged.
×
Make an Enquiry - Molecular
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
  • This field is for validation purposes and should be left unchanged.
×
Make an Enquiry - Future Diagnostics
×
Make an Enquiry - RX series (Product)
×
Make an Enquiry - Quality Control
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Make an Enquiry - RIQAS
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Make an Enquiry - Reagents
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Por favor, introduzca sus datos para ver nuestro último seminario
×
Wyślij zapytanie
  • Rejestracja na naszej liście mailowej jest szybka i łatwa. Nie chcemy wysyłać e-maili zawierających spam lub wiadomości, które są automatycznie przekierowywane do kosza. W zawiązku z czym firma Randox deklaruje, że będzie wysyłac tylko informacje na temat nowych produktów,akutalizacji obecnych, trendów rynkowych, wydarzeń branżowych itp. Firma Randox Laboraotries obiecuje, że Państwa dane nie będą nigdzie przekazane, a przechowywanie owych danych będzie się odbywało z zachowaniem największego bezpieczeństwa. Prosimy o przeczytani naszje Polityki Prywatności.
×
Wyślij zapytanie
  • Rejestracja na naszej liście mailowej jest szybka i łatwa. Nie chcemy wysyłać e-maili zawierających spam lub wiadomości, które są automatycznie przekierowywane do kosza. W zawiązku z czym firma Randox deklaruje, że będzie wysyłac tylko informacje na temat nowych produktów,akutalizacji obecnych, trendów rynkowych, wydarzeń branżowych itp. Firma Randox Laboraotries obiecuje, że Państwa dane nie będą nigdzie przekazane, a przechowywanie owych danych będzie się odbywało z zachowaniem największego bezpieczeństwa. Prosimy o przeczytani naszje polityki prywatności.
×
Wyślij zapytanie